Statement by Prof. Jallal Toufiq, President,
International Narcotics Control Board (INCB)
Sixty-eighth session of the Commission on Narcotic Drugs
Item 5 (a) Changes in the scope of control of substances
12 March 2025, Vienna, Austria
Mr. Chair, Excellencies, Ladies and Gentlemen,
This year, there is no scheduling recommendation under the 1988 Convention before the Commission. However, on 4 September 2024 I informed the Chair of the Commission of a proposal to move the methyl ester of 3,4-MDP-2-P methyl glycidic acid from the body of Table I of that Convention to the footnote introduced in CND decision 67/25.
The proposal follows the Board's observation of an inconsistency with regard to the manner in which the esters of 3,4-MDP-2-P methyl glycidic acid were presented in Table I of the 1988 Convention. Specifically, while seven esters of 3,4-MDP-2-P methyl glycidic acid had been included in a footnote to Table I of the 1988 Convention, which was introduced in accordance with Commission decision 67/25 of March 2024, the methyl ester, which had been added to Table I of the 1988 Convention in November 2019, was still included in the body of that table - as 3,4-MDP-2-P methyl glycidate.
The Board therefore proposed that the methyl ester be removed from the body of Table I of the 1988 Convention and instead be included in the same footnote (as "methyl ester") so that it appears together with the other seven esters, as shown in the slide.
This would also be consistent with the presentation, in accordance with Commission decision 67/17, of P-2-P methyl glycidic acid and its esters in Table I of the 1988 Convention.
Thank you.